Mr. Mark Upsdell reports

RAPID DOSE THERAPEUTICS AND AAVISHKAR GRANTED MONOLAYER QUICKSTRIP NICOTINE PATENT, ADVANCING RDT'S GLOBAL COMMERCIALIZATION STRATEGY

Rapid Dose Therapeutics Corp., together with its development partner Aavishkar Oral Strips Pvt. Ltd., has been granted a second key patent covering its QuickStrip nicotine oral-film technology.

The Patent Office, government of India, has granted patent No. 599533, arising from patent application No. 202441055746, filed July 22, 2024. The patent, titled "Nicotine Oral Film and Process for Preparation Thereof," was granted Aug. 17, 2026, to Aavishkar Oral Strips and Rapid Dose for a 20-year term calculated from the filing date.

The new patent covers Rapid Dose's monolayer nicotine oral-film technology, including related formulation and manufacturing processes. It follows the March, 2026, grant of Indian patent No. IN 582202 covering the companies' QuickStrip nicotine bilayer oral film and related formulation and manufacturing processes.

Together, the monolayer and bilayer patents provide intellectual property protection across multiple configurations of Rapid Dose's nicotine oral-film platform, further strengthening the intellectual property foundation underlying the company's commercialization strategy.

The issuance of the patent represents another milestone in Rapid Dose's strategy to build a broad, defensible intellectual property portfolio around novel oral nicotine delivery technology and ultimately commercialize that technology in regulated markets internationally.

Protecting the technology and executing the strategy

Rapid Dose believes intellectual property protection is particularly important as the company moves QuickStrip nicotine from development and validation toward commercialization.

The company's strategy has been deliberate: develop differentiated oral-film nicotine technology; establish international intellectual property protection; validate the technology with sophisticated industry participants; advance regulatory and commercial readiness; and ultimately monetize the platform through licensing, partnerships and direct commercial opportunities.

The granting of this latest patent represents another tangible step in that progression, adding a second granted nicotine oral-film patent to Rapid Dose's intellectual property portfolio.

Rapid Dose and Aavishkar began pursuing broader international protection through Patent Cooperation Treaty filings announced in May, 2025. The PCT framework provides a pathway to seek patent protection across as many as 158 jurisdictions, subject to applicable national and regional examination and grant requirements, reflecting the companies' strategy from the outset to develop QuickStrip nicotine as a technology with global rather than single-market potential.

"This second patent is another important demonstration of our continued execution against the strategy we have communicated to shareholders," said Mark Upsdell, chief executive officer of Rapid Dose Therapeutics. "We set out to develop a differentiated nicotine delivery platform, establish meaningful intellectual property protection around the technology and advance it toward commercialization. With granted patents now covering both monolayer and bilayer nicotine oral-film technologies, we are continuing to build a stronger foundation for the long-term commercial value of QuickStrip.

"Patents are not simply technical milestones for RDT -- they are strategic commercial assets," continued Mr. Upsdell. "As we engage with major industry participants and evaluate opportunities internationally, protecting our formulations, product configurations and manufacturing processes strengthens the value proposition of QuickStrip and supports our ability to negotiate partnership and commercialization opportunities from a stronger position."

Positioned within a large and growing global market

The opportunity Rapid Dose is pursuing exists within the global tobacco and nicotine landscape.

According to the World Health Organization, approximately 1.2 billion people worldwide use tobacco, illustrating the scale of global tobacco use and the continuing need for innovation in non-combustible nicotine delivery approaches for adult consumers.

More specifically, the global modern oral nicotine products market was valued at approximately $7.96-billion (U.S.) in 2024 and is projected by Grand View Research to reach approximately $39-billion (U.S.) by 2033, representing a compound annual growth rate of approximately 19.0 per cent from 2025 to 2033.

QuickStrip is being developed as a differentiated format for this market. Rather than a cigarette, vaping device, pouch, gum, lozenge or patch, QuickStrip utilizes a thin oral film designed to deliver nicotine through the oral mucosa in a discreet, portable and device-free format. These successful patent applications support an alternative delivery methodology for nicotine use.

Rapid Dose's development work has included customizable nicotine strengths, dissolution profiles, product configurations and packaging, providing the platform with the potential to be adapted to different commercial and regulatory requirements across international markets.

Management believes the scale of global tobacco use, continued growth in modern oral nicotine products and increasing industry investment in non-combustible delivery formats create a significant long-term opportunity for innovation in differentiated nicotine-delivery technologies such as QuickStrip.

Strengthening the global collaboration

The latest patent grant also comes at an important stage in Rapid Dose's relationship with a global leader in the nicotine product industry.

On July 7, 2026, Rapid Dose announced the execution of a memorandum of understanding extending the parties' continuing collaboration following completion of their previous precommercialization development agreement.

Under the MOU, the parties are advancing a collaboration agreement addressing the milestones required to assess commercialization. The work and services to be completed in 2026, encompass technical validation, product benchmarking, regulatory affairs, branding, commercial assessment and launch readiness.

The relationship has progressed from initial product development activity to a structured evaluation of the requirements for commercialization of QuickStrip nicotine products.

Management believes the granting of an additional patent provides further impetus to that process by strengthening the intellectual property foundation surrounding the product being evaluated.

"Our collaboration with a global nicotine industry leader and our patent strategy are directly connected," said Mr. Upsdell. "A multinational commercial partner needs confidence not only in the technical performance and consumer relevance of a technology, but also in the intellectual property protecting it. Each milestone we achieve -- technical, regulatory, intellectual property and commercial -- advances the overall program. We believe this latest patent further strengthens the foundation as the parties work toward potential commercialization."

The collaboration agreement announced in July provides a dedicated period focused on market launch milestones and establishes a structured pathway toward potential future licensing or commercialization arrangements although there can be no assurance that a definitive commercial agreement will ultimately be completed.

Building value through execution

The company believes its recent milestones demonstrate a continued progression of its nicotine strategy, including:

• International patent applications intended to support broader geographic intellectual property protection;
• Two granted patents covering monolayer and bilayer nicotine oral-film technologies;
• Nearly three years of development and engagement with a global nicotine industry participant;
• Progression from precommercialization development into a collaboration agreement focused on commercialization readiness;
• Continuing technical development and regulatory submission for approval of QuickStrip nicotine oral thin-film strip technologies.

"We want shareholders to recognize the progression," concluded Mr. Upsdell. "RDT has moved from invention, to development, to international patent filings, to granted intellectual property, while simultaneously advancing technical validation and commercial discussions with a global industry leader. These are interconnected elements of the strategy we established for QuickStrip nicotine, and we continue to execute against that strategy.

"Our objective remains to build QuickStrip nicotine into a protected and commercially valuable global platform. We believe having multiple granted patents, international patent protection under way, an advanced industry collaboration and multiple potential routes to market places RDT in its strongest position to date to pursue that objective."

Rapid Dose and Aavishkar will continue to advance their intellectual property strategy while Rapid Dose progresses technical, regulatory and commercialization activities with existing and prospective commercial partners.

Any commercial introduction of QuickStrip nicotine remains subject to applicable regulatory requirements and approvals in the relevant jurisdiction.

Any definitive licensing, commercialization or other agreement with Rapid Dose's global nicotine industry collaborator remains subject to completion of the parties' continuing work, negotiations and execution of definitive agreements.

Rapid Dose Therapeutics will continue to update shareholders as material milestones are achieved.

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient.

We seek Safe Harbor.